• Something wrong with this record ?

Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis

H. Mostafaei, H. Salehi-Pourmehr, S. Jilch, GL. Carlin, K. Mori, F. Quhal, B. Pradere, NC. Grossmann, E. Laukhtina, VM. Schuettfort, A. Aydh, R. Sari Motlagh, F. König, CG. Roehrborn, S. Katayama, P. Rajwa, S. Hajebrahimi, SF. Shariat

. 2022 ; 8 (4) : 1072-1089. [pub] 20210922

Language English Country Netherlands

Document type Journal Article, Meta-Analysis, Review, Systematic Review, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22033358

CONTEXT: The choice of the most efficacious drug for patients with idiopathic overactive bladder (IOAB) remains challenging. OBJECTIVE: The aim of this network meta-analysis was to determine the most efficacious oral antimuscarinic or β-adrenoceptor agonist accounting for adverse events for the management of IOAB. EVIDENCE ACQUISITION: A comprehensive electronic search was done in MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, and Ovid for studies in any language in February 2021 considering the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. We included all randomized controlled trials assessing oral antimuscarinics or β-adrenoceptor agonists for the treatment of IOAB. We determined the effect of specific bothersome symptoms separately. EVIDENCE SYNTHESIS: Fifty-four articles were included in our analysis. The most efficacious agents considering the evaluated outcomes were oxybutynin 15 mg/d in reducing incontinence episodes, imidafenacin 0.5 mg/d together with solifenacin 10 and 5 mg/d in reducing micturition episodes, fesoterodine 4 and 8 mg/d as well as solifenacin 10 mg/d in reducing urgency episodes, imidafenacin 0.5 mg/d and solifenacin 10 mg/d in reducing urgency urinary incontinence episodes, and solifenacin 10 mg/d, vibegron 50 mg/d, and fesoterodine 8 mg/d in improving the voided volume. Gastrointestinal problems, especially due to antimuscarinic agents, were the most prevalent adverse events. CONCLUSIONS: Taken together, there is only minimal difference between the efficacy of oral antimuscarinics and that of β-adrenoceptor agonists. Although finding the best medication for all is impossible, finding the best treatment for every individual patient can be done by considering the efficacy of a medicine for the most bothersome symptom(s) in balance with drug-specific adverse events. PATIENT SUMMARY: This study aimed to find the most efficient oral medication to treat overactive bladder, taking into consideration the adverse events. Based on our study, there is a minimal difference in the efficacy between the two major drug classes used to treat overactive bladder. Gastrointestinal problems were the most common adverse events in medical treatment of overactive bladder. Selection of the best treatment is possible through shared decision-making between the doctor and the patient based on the patient's most bothersome symptom. We provide a framework for physicians to facilitate shared decision-making with each individual patient.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033358
003      
CZ-PrNML
005      
20230131151845.0
007      
ta
008      
230120s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euf.2021.08.011 $2 doi
035    __
$a (PubMed)34563481
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Research Center for Evidence-Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
245    10
$a Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis / $c H. Mostafaei, H. Salehi-Pourmehr, S. Jilch, GL. Carlin, K. Mori, F. Quhal, B. Pradere, NC. Grossmann, E. Laukhtina, VM. Schuettfort, A. Aydh, R. Sari Motlagh, F. König, CG. Roehrborn, S. Katayama, P. Rajwa, S. Hajebrahimi, SF. Shariat
520    9_
$a CONTEXT: The choice of the most efficacious drug for patients with idiopathic overactive bladder (IOAB) remains challenging. OBJECTIVE: The aim of this network meta-analysis was to determine the most efficacious oral antimuscarinic or β-adrenoceptor agonist accounting for adverse events for the management of IOAB. EVIDENCE ACQUISITION: A comprehensive electronic search was done in MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, and Ovid for studies in any language in February 2021 considering the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. We included all randomized controlled trials assessing oral antimuscarinics or β-adrenoceptor agonists for the treatment of IOAB. We determined the effect of specific bothersome symptoms separately. EVIDENCE SYNTHESIS: Fifty-four articles were included in our analysis. The most efficacious agents considering the evaluated outcomes were oxybutynin 15 mg/d in reducing incontinence episodes, imidafenacin 0.5 mg/d together with solifenacin 10 and 5 mg/d in reducing micturition episodes, fesoterodine 4 and 8 mg/d as well as solifenacin 10 mg/d in reducing urgency episodes, imidafenacin 0.5 mg/d and solifenacin 10 mg/d in reducing urgency urinary incontinence episodes, and solifenacin 10 mg/d, vibegron 50 mg/d, and fesoterodine 8 mg/d in improving the voided volume. Gastrointestinal problems, especially due to antimuscarinic agents, were the most prevalent adverse events. CONCLUSIONS: Taken together, there is only minimal difference between the efficacy of oral antimuscarinics and that of β-adrenoceptor agonists. Although finding the best medication for all is impossible, finding the best treatment for every individual patient can be done by considering the efficacy of a medicine for the most bothersome symptom(s) in balance with drug-specific adverse events. PATIENT SUMMARY: This study aimed to find the most efficient oral medication to treat overactive bladder, taking into consideration the adverse events. Based on our study, there is a minimal difference in the efficacy between the two major drug classes used to treat overactive bladder. Gastrointestinal problems were the most common adverse events in medical treatment of overactive bladder. Selection of the best treatment is possible through shared decision-making between the doctor and the patient based on the patient's most bothersome symptom. We provide a framework for physicians to facilitate shared decision-making with each individual patient.
650    _2
$a benzhydrylové sloučeniny $7 D001559
650    _2
$a lidé $7 D006801
650    _2
$a antagonisté muskarinových receptorů $x terapeutické užití $7 D018727
650    _2
$a síťová metaanalýza $7 D000071076
650    _2
$a adrenergní receptory $x terapeutické užití $7 D011941
650    _2
$a solifenacin sukcinát $x škodlivé účinky $7 D000069464
650    12
$a hyperaktivní močový měchýř $x diagnóza $x farmakoterapie $7 D053201
650    12
$a inkontinence moči $x farmakoterapie $7 D014549
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a přehledy $7 D016454
655    _2
$a systematický přehled $7 D000078182
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Salehi-Pourmehr, Hanieh $u Research Center for Evidence-Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
700    1_
$a Jilch, Sandra $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Carlin, Greta Lisa $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Grossmann, Nico C $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Hospital Zurich, Zurich, Switzerland
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
700    1_
$a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Aydh, Abdulmajeed $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; King Faisal Medical City, Abha, Saudi Arabia
700    1_
$a Sari Motlagh, Reza $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
700    1_
$a König, Frederik $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Roehrborn, Claus G $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
700    1_
$a Katayama, Satoshi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
700    1_
$a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland
700    1_
$a Hajebrahimi, Sakineh $u Research Center for Evidence-Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; European Association of Urology research foundation, Arnhem, The Netherlands. Electronic address: shahrokh.shariat@meduniwien.ac.at
773    0_
$w MED00193513 $t European urology focus $x 2405-4569 $g Roč. 8, č. 4 (2022), s. 1072-1089
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34563481 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151841 $b ABA008
999    __
$a ok $b bmc $g 1891891 $s 1184693
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 8 $c 4 $d 1072-1089 $e 20210922 $i 2405-4569 $m European urology focus $n Eur Urol Focus $x MED00193513
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Archiving options